Welcome!

News Feed Item

Neurostimulation: Technologies and Global Markets

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Neurostimulation: Technologies and Global Markets

http://www.reportlinker.com/p02070063/Neurostimulation-Technologies-and-...

 

REPORT HIGHLIGHTS

 

The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.

 

This report provides:

 

 

An overview of the global market for neurostimulation devices, many of which currently are in clinical trials or undergoing development to treat a range of disorders, including epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, urinary tract disorders, and drug addiction

Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018

A focus on individual disorders and variety of neurostimulation options, which include deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation, and closed-loop/responsive stimulation

Examination of positive market impacts, which include increasing acceptance of neurostimulation devices for multiple applications, an aging population market, and technological advancements; as well as negative impacts, which include current device recalls, risks of neurostimulation devices, and investment and funding for new technological advancements

Evaluations of new product launches, current promising clinical trials, and the patent/technological pipeline

Comprehensive company profiles of major players.

 

INTRODUCTION

 

Neurostimulation incorporates technological advancements from a variety of fields including science, medicine and bioengineering. The main goal through these technologies is to develop implantable electrical devices to improve the quality of human life and day-to-day human functioning. This involves the process of electrically inhibiting or activating the functioning of the peripheral, central or autonomic nervous systems. The earliest implantable neurostimulation devices were spinal cord stimulators and stimulators to treat cardiovascular disease. In the 1970s, deep brain stimulator devices were introduced. It was around this time that the U.S. Food and Drug Administration (FDA) required implantable devices to be regulated and compliable with patient safety measures. From the 1980s to today, neurostimulators have been mainly used to treat movement disorders.

 

The neurostimulation device industry has seen rapid growth in the past decade. These technological advancements have not only led to improvements in existing neurostimulation devices, but they have also aided the development of the next generation of devices.Neurostimulation devices are increasingly used for pain management. Each year it is estimated that over 100 million people globally suffer from chronic pain. Currently drug therapies are the primary treatment option; however, in the long run these therapies have proved to be ineffective. As a result, in the current neurostimulation industry devices are of increasing interest for treating chronic pain. Recently a large number of neurostimulation devices have begun clinical trials or are undergoing development to treat a range of disorders including: epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, cardiovascular disorders, movement disorders, gastrointestinal disorders, urinary tract disorders, sensory disorders and drug addiction. This opens up a wider market of applications for neurostimulation devices.

 

This also points to the fact that a wide variety of clinical specialists, apart from neurosurgeons and neurologists, would be interested in applying the therapies enabled by neurostimulation.Currently, the market is underdeveloped despite technological advances due to low medical acceptance and equally low consumer awareness. Patients still fear the prospect of having a foreign object implanted into their bodies. This is anticipated to change with the commercialization of technologically advanced neurostimulators, physician training, increased venture capital and government funding and considerably due to the expansion of health insurance to the underinsured and uninsured. It should be noted that even with the expansion of health insurance, often health insurance providers do not offer full reimbursement for neurostimulation devices.

 

This is due to some providers being ill-informed and not being fully clear on the concept of neurostimulation as a viable treatment option. It becomes a priority for leading medical device manufacturers and physicians to inform insurance providers about the benefits and success stories of neurostimulation devices. This will lead to the successful implementation of neurostimulation devices on the market from manufacturing to implantation and through patient therapy.

 

STUDY GOALS AND OBJECTIVES

 

This report, Neurostimulation, from BCC Research includes forecasted trends and sales through 2018. Current market leaders, new technologies and factors influencing low and high demand are discussed. Neurostimulation ranges from noninvasive to minimally invasive to fully invasive. Depending upon the application, various neurostimulation devices are currently on the market.

 

This report is particularly focused on individual disorders and discusses a variety of neurostimulation options for each disorder—including deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation and closed-loop/responsive stimulation. Finally, the report includes information about market share, new product launches, promising technologies and current clinical trials.

 

REASONS FOR DOING THE STUDY

 

As of 2011, the size of the neurostimulation market was estimated at 4.2 billion. This market serves a patient population with both sensory and motor neural deficits. Compared to other medical device markets, the neurostimulation market can still be considered as an emerging market. At this point in time, the exiting neurostimulation technologies of spinal cord stimulation, cochlear implants and vagal nerve stimulation are widely successful. The success of these technologies with current advances in imaging technologies can provide an increase in the number of clinical applications for neurostimulation devices. These applications will also increase with the establishment of specialized medical training and a patient population eligible to benefit from the neurostimulation devices.In the past few years, these advances have led to the development of a large number of small start-up firms working on exciting new technologies. This has created a competitive market place. This report will provide the reader with an overview of neurostimulation devices available for treating individual disorders along with an overview of company profiles.

 

SCOPE OF REPORT

 

This report is a business tool that primarily will be helpful in examining trends in the market for neurostimulation devices. It begins with an overview of neurostimulation devices, key players, entry-level players, market trend analysis and factors influencing future incidence. It will also include market analysis by clinical disorder, including annual incidence, trend analysis and factors influencing future predicted surgical volume. Finally, the report will cover market share and information on key neurostimulation device manufacturers.

 

INTENDED AUDIENCE

 

This report is intended for anyone interested in better understanding the role of the rapidly growing neurostimulation technologies of the broader neuromodulation markets.Executives, consultants, trade associations, clinicians and marketing professionals in the medical device industry, health insurance industry and experts in the neuroscience and neurosurgery fields would benefit from this report. Additionally, stock analysts, venture capitalists funders and investors focused on the neuromodulation markets or those who are interested in expanding markets for neurostimulation devices would also benefit. Manufacturers and distributors of the neurostimulation technologies discussed in this report are also an intended audience.

Chapter- 1: INTRODUCTION 4

 

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC RESEARCH REPORTS

BCC RESEARCH ONLINE SERVICES

DISCLAIMER

 

Chapter- 2: SUMMARY 3

 

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018

Figure 0 A : DISTRIBUTION OF NEUROSTIMULATION DEVICES BY TYPE OF DISORDER CATEGORY 2012-2018

Figure 0 B : GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY 2012-2018

 

Chapter- 3: OVERVIEW OF NEUROSTIMULATION DEVICES

 

MARKET TRENDS (TECHNOLOGIES) AND MARKET SHARE (KEY PLAYERS AND ENTRY LEVEL)

POSITIVE MARKET IMPACT

NEGATIVE MARKET IMPACT

 

Chapter- 4: MARKET FOR NEUROSTIMULATION DEVICES

 

NEUROSTIMULATION FOR PAIN MANAGEMENT

NEUROSTIMULATION FOR MOVEMENT DISORDERS

NEUROSTIMULATION FOR NEUROPSYCHIATRIC DISORDERS

NEUROSTIMULATION FOR STROKE AND TRAUMATIC BRAIN INJURY

NEUROSTIMULATION FOR CARDIOVASCULAR DISORDERS

NEUROSTIMULATION FOR GASTROINTESTINAL DISORDERS

NEUROSTIMULATION FOR URINARY AND RECTAL DISORDERS

NEUROSTIMULATION FOR SENSORY DISORDERS

ADAPTIVE NEUROSTIMULATION THERAPY

 

Chapter- 5: COMPANY PROFILES

 

ADVANCED BIONICS, LLC

ALEVA NEUROTHERAPEUTICS SA

ATROTECH OY

AUTONOMIC TECHNOLOGIES INC.

AVERY BIOMEDICAL DEVICES, INC.

BIONESS INC.

BIOTRONIK SE & CO.KG

BOSTON SCIENTIFIC CORPORATION

CERBOMED GMBH

COCHLEAR AMERICAS

CVRX INC.

CYBERONICS, INC.

ENTEROMEDICS INC.

MED-EL MEDICAL ELECTRONICS

MEDTRONIC, INC.

NEUROMETRIX INC.

NEURONETICS, INC.

NEUROPACE INC.

NEUROSIGMA

NEVRO CORPORATION

SECOND SIGHT MEDICAL PRODUCTS, INC.

SPINAL MODULATION INC.

SPR THERAPEUTICS LLC

ST. JUDE MEDICAL

UROPLASTY, INC.

ZYNEX MEDICAL, INC.

 

 

List of Tables

 

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018

Table 1 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS

Table 2 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS

Table 3 : HEARING LOSS DEVICE GLOBAL MARKET DISTRIBUTION

Table 4 : MANUFACTURERS OF HEARING LOSS DEVICES MARKET SHARE

Table 5 : MANUFACTURERS OF OVERACTIVE BLADDER DEVICES MARKET SHARE IN NORTH AMERICA

Table 6 : MARKET SHARE OF MANUFACTURERS OF EPILEPSY DEVICES

Table 7 : MARKET SHARE OF MANUFACTURERS OF FOOT DROP DEVICES

Table 8 : MARKET SHARE OF MANUFACTURERS OF DIABETES/OBESITY DEVICES, 2012

Table 9 : RETINAL DEGENERATION MANUFACTURERS' MARKET SHARE

Table 10 : PREMARKET APPROVALS (PMA) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 11 : PREMARKET NOTIFICATION (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 12 : CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 13 : CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 14 : PREMARKET APPROVALS (PMA) FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES

Table 15 : CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES

Table 16 : PREMARKET APPROVALS (PMA) FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 17 : CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 18 : AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 19 : PREMARKET APPROVALS (PMA) FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 20 : CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 21 : PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 22 : PREMARKET APPROVALS (PMA) FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES

Table 23 : CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES

Table 24 : NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 25 : PREMARKET APPROVALS (PMA) FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES

Table 26 : CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 27 : NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 28 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Table 29 : DISTRIBUTION OF RANKINGS FOR EPILEPSY BY GLOBAL REGIONS.

Table 30 : GLOBAL PREVALENCE OF EPILEPSY

Table 31 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN MALES

Table 32 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Table 33 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 34 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 35 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 36 : PREMARKET APPROVALS (PMA) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 37 : PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 38 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES.

Table 39 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES

Table 40 : NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 41 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL MALE POPULATION OF 2004

Table 42 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL FEMALE POPULATION OF 2004

Table 43 : DISTRIBUTION OF RANKINGS FOR SCHIZOPHRENIA BY REGION, 2010

Table 44 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA 2010

Table 45 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010

Table 46 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010

Table 47 : CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES

Table 48 : NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 49 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Table 50 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER. AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Table 51 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER, AS A PERCENTAGE OF TOTAL DALYS

Table 52 : DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006

Table 53 : DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP

Table 54 : CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 55 : CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 56 : NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 57 : GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006

Table 58 : RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010

Table 59 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, 2010

Table 60 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010

Table 61 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010

Table 62 : CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 63 : NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 64 : CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 65 : NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 66 : DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010

Table 67 : GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004

Table 68 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Table 69 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Table 70 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS, 2006

Table 71 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010

Table 72 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010

Table 73 : CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES

Table 74 : NEUROSTIMULATION AND BI-POLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 75 : DISTRIBUTION OF RANKINGS FOR DEPRESSION BY GLOBAL REGIONS, 2010

Table 76 : GLOBAL PREVALENCE OF DEPRESSION, 2004

Table 77 : GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 78 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 79 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 80 : PRE-MARKET APPROVALS (PMA) FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES

Table 81 : CLINICAL TRIALS FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES

Table 82 : NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 83 : RANK OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010

Table 84 : GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004

Table 85 : CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 86 : NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 87 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., FROM 1997 TO 2007

Table 88 : CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 89 : NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 90 : CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 91 : NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 92 : PRE-MARKET APPROVALS (PMA) FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 93 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 94 : NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 95 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES IN THE MALE POPULATION OF 2004

Table 96 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES, IN THE FEMALE POPULATION OF 2004

Table 97 : PRE-MARKET APPROVALS (PMA) FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 98 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY ASSOCIATED NEUROSTIMULATION DEVICES

Table 99 : NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 100 : OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008

Table 101 : OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008

Table 102 : DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010

Table 103 : DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009 TO 2010

Table 104 : PERCENTAGE OF OBESITY AMONG MALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008

Table 105 : PERCENTAGE OF OBESITY AMONG FEMALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008

Table 106 : DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 107 : DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 108 : DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 109 : CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 110 : NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 111 : PRE-MARKET APPROVALS (PMA) FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES

Table 112 : CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 113 : NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 114 : PREMARKET APPROVALS (PMA) FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES

Table 115 : CLINICAL TRIALS FOR FECAL INCONTINENCE ASSOCIATED NEUROSTIMULATION DEVICES

Table 116 : NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 117 : DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010

Table 118 : GLOBAL PREVALENCE OF MODERATE OR GREATER HEARING LOSS DISEASE, 2004

Table 119 : GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004

Table 120 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY, INCLUDING HEARING, LOSS IN MALES, 2004

Table 121 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY INCLUDING HEARING LOSS, IN FEMALES

Table 122 : PREMARKET APPROVALS (PMA) FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 123 : CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 124 : NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 125 : CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 126 : NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 127 : CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY

 

List of Figures

 

Figure 1 : MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER

Figure 2 : MARKET SHARE OF HEARING LOSS NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER

Figure 3 : SALES DISTRIBUTION OF DIABETES/OBESITY NEUROSTIMULATION DEVICES BY MANUFACTURER, 2012

Figure 4 : DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK, BY CONDITION

Figure 5 : DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK, BY BODY PARTS INCLUDING BACK

Figure 6 : DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP

Figure 7 : DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN, BY AGE GROUP

Figure 8 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Figure 9 : DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP

Figure 10 : GLOBAL PREVALENCE OF PARKINSON'S DISEASE

Figure 11 : NUMBER OF DEATHS GLOBALLY DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 12 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 13 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 14 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Figure 15 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING PARKINSON'S DISEASE AS A PERCENTAGE OF TOTAL DALYS IN MALES

Figure 16 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Figure 17 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS

Figure 18 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS

Figure 19 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006

Figure 20 : GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004

Figure 21 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 22 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 23 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 24 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 25 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 26 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 27 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006

Figure 28 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 29 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 30 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 31 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007

Figure 32 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007

Figure 33 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007

Figure 34 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007

Figure 35 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007

Figure 36 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008

Figure 37 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005-2008

Figure 38 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE, IN THE MALE POPULATION OF 2004

Figure 39 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE IN THE FEMALE POPULATION OF 2004

 

 

To order this report: Neurostimulation: Technologies and Global Markets

http://www.reportlinker.com/p02070063/Neurostimulation-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 18th International CloudExpo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty ...
Companies can harness IoT and predictive analytics to sustain business continuity; predict and manage site performance during emergencies; minimize expensive reactive maintenance; and forecast equipment and maintenance budgets and expenditures. Providing cost-effective, uninterrupted service is challenging, particularly for organizations with geographically dispersed operations.
As cloud and storage projections continue to rise, the number of organizations moving to the cloud is escalating and it is clear cloud storage is here to stay. However, is it secure? Data is the lifeblood for government entities, countries, cloud service providers and enterprises alike and losing or exposing that data can have disastrous results. There are new concepts for data storage on the horizon that will deliver secure solutions for storing and moving sensitive data around the world. ...
18th Cloud Expo, taking place June 7-9, 2016, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises are using some...
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
SoftLayer operates a global cloud infrastructure platform built for Internet scale. With a global footprint of data centers and network points of presence, SoftLayer provides infrastructure as a service to leading-edge customers ranging from Web startups to global enterprises. SoftLayer's modular architecture, full-featured API, and sophisticated automation provide unparalleled performance and control. Its flexible unified platform seamlessly spans physical and virtual devices linked via a world...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life ...
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.